Growth hormone treatment reduces peripheral thyroid hormone action in girls with Turner Syndrome

SUSPERREGUY S; MIRAS MB; MONTESINOS, MM; MASCANFRONI ID; MUÑOZ L; SOBRERO G; SILVANO L; MASINI-REPISO AM; COLEONI AH; TARGOVNIK HM; PELLIZAS, CG

Blackwell Publishing

Año: 2007 vol. 67 p. 629 - 629

p>Turner syndrome (TS) is an indication for GH therapy in spite of the modest growth response. Somatic growth depends not  only on GH insulin-like growth factor I (IGF-I) axis but also on thyroid hormone (TH) status. We have previously reported that  supraphysiological IGF-I levels diminished TH actions in rat tissues by reducing the nuclear TH receptor (TR). GH treatment to TS patients  induces high IGF-I levels and therefore a reduction of TH action in tissues may be expected. We aimed at evaluating the effect of GH therapy  in TS girls on peripheral TH action.  Design and patients   We set up a reverse transcription-polymerase chain reaction (RT-PCR) for TR mRNA estimation in peripheral blood mononuclear cells  (PBMC) and compared TR mRNA levels from 10 normal, 10 TS and 10 TS girls under GH therapy (0·33 mg/kg/week for 0·5–2 years).  Measurements  After RNA extraction from PBMC, TR and beta-actin mRNAs were